KMT2A fusions account for 78% of fusions in leukemia and the frequencies of different forms vary from 0.05 to 35% (Additional file 2: Table S1), suggesting that KMT2A fusions may be an important driver of leukemia. This evidence concerns the gene KMT2A and leukemia.